• STXS

Shield Therapeutics reports steady Q3 growth and financial plans

Shield Therapeutics reported a positive Q3 2024 with $7.2M in revenues from ACCRUFeR®, a 20% increase in prescriptions, and plans for financial restructuring and cost reductions.